Benitec Biopharma Appoints Ernst & Young as Independent Auditor for FY2027

What Happened
Benitec Biopharma Inc. (BNTC) filed a Form 8-K (Item 4.01) reporting that it has engaged Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending June 30, 2027. The Company had previously disclosed the pending engagement on a Form 8-K filed September 24, 2026. EY completed its client acceptance procedures on September 28, 2026, and an engagement letter was executed on September 29, 2026. The 8-K was signed by CEO Dr. Jerel A. Banks on September 30, 2026.

Key Details

• Engagement subject to and completed client acceptance: EY completed acceptance procedures on September 28, 2026.
• Formal appointment: engagement letter executed on September 29, 2026.
• Applicable period: engagement covers the fiscal year ending June 30, 2027.
• Filing: Change of certifying accountant reported under Item 4.01 in the Form 8-K filed September 30, 2026.

Why It Matters
A change of independent auditor is a notable corporate governance event. For investors, this means future audited financial statements for the covered fiscal year will be prepared and reviewed by EY rather than the prior auditor. The filing shows the appointment is finalized (client acceptance and engagement letter executed), but the 8-K does not state any disagreements with the previous auditor or reasons for the change. Investors should watch upcoming financial filings for any changes in audit fees, audit scope, timing of filings, or disclosures that could affect financial reporting.